Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
Athletes tied to Iowa gambling sting seek damages in civil lawsuit against state and investigatorsMadrid replacements too good for Sociedad and take step closer to La Liga titleJudge upholds disqualification of challenger to judge in Trump’s Georgia election interference caseMLB presence in Mexico goes beyond just hosting another regularBayern Munich signals decision is near on new coach to replace Thomas TuchelKing Charles III to resume public duties after cancer treatmentThe first round of the NFL draft turns into a QB bonanza with a recordSam Kerr's bid to get raciallyMilitary veteran charged with attempting to make ricin to remain jailedWade Rousse named new president of Louisiana's McNeese State University
3.4447s , 6500.7421875 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,Global Gazette news portal